Journal of Clinical Oncology August 10, 2014

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial

Marie-Cécile Le Deley, Michael Paulussen, Ian Lewis, et al.

Bottom Line

A large randomized non-inferiority trial demonstrating that cyclophosphamide is non-inferior to ifosfamide as consolidation therapy for standard-risk localized Ewing sarcoma, offering a more favorable renal toxicity profile.

Key Findings

1. A total of 856 patients were randomized to receive either 7 courses of VAC (n=431) or VAI (n=425) consolidation following intensive VIDE induction therapy [6.1.5].

2. After a median follow-up of 5.9 years, the 3-year EFS rates were 75.4% for the VAC arm and 78.2% for the VAI arm.

3. The difference in 3-year EFS was -2.8% (91.4% CI, -7.8% to 2.2%), successfully meeting the pre-specified non-inferiority margin of -8.5%.

4. The hazard ratio for an event (HRevent) was 1.12 (91.4% CI, 0.89 to 1.41) in the intention-to-treat analysis, confirming non-inferiority.

5. Overall survival at 3 years was comparable between the two groups, with an HR for death of 1.09 (91.4% CI, 0.84 to 1.42).

6. The VAC arm was associated with significantly fewer grade 2 to 4 acute tubular renal toxicities (16% vs 31%) and fewer treatment modifications (<1% vs 7%), despite a slightly higher incidence of thrombocytopenia (45% vs 35%).

Study Design

Design

Randomized Controlled Trial (Non-inferiority)

Open-Label

Sample

856

Patients

Duration

5.9 yr

Median

Setting

Multicenter, Europe

Population Patients with standard-risk localized Ewing sarcoma (defined by good histologic response with <10% viable cells to induction, or small tumor <200 mL completely resected or treated with radiotherapy only).

Intervention VAC (vincristine, dactinomycin, and cyclophosphamide) consolidation for 7 courses

Comparator VAI (vincristine, dactinomycin, and ifosfamide) consolidation for 7 courses

Outcome 3-year event-free survival (EFS)

Study Limitations

• The open-label design could introduce bias in the reporting of subjective toxicities and the clinical decision to modify treatment doses [6.1.2].

• The acceptable non-inferiority margin for EFS (-8.5%) is relatively wide, meaning a small but clinically relevant efficacy difference in favor of ifosfamide cannot be entirely ruled out.

• The findings are specifically applicable only to patients with localized, standard-risk disease and cannot be extrapolated to patients with high-risk or metastatic Ewing sarcoma.

Clinical Significance

By confirming that cyclophosphamide is non-inferior to ifosfamide for standard-risk consolidation, the Euro-EWING99-R1 trial established VAC as a standard of care that mitigates the risk of severe acute and late renal toxicity associated with ifosfamide. This optimization significantly improves the tolerability of treatment for long-term pediatric and young adult survivors of Ewing sarcoma.

Historical Context

Ewing sarcoma is an aggressive tumor that requires intensive multimodal therapy. Historically, regimens utilized both cyclophosphamide and ifosfamide, but ifosfamide is known for causing significant renal and neurologic toxicities. The Euro-E.W.I.N.G. 99 trial was a massive pan-European cooperative study designed to refine therapy based on risk stratification. While the R2 and R3 arms evaluated high-dose busulfan-melphalan in high-risk and metastatic patients, the R1 randomization addressed the most common subgroup—standard-risk localized disease. By definitively proving VAC could safely replace VAI, the trial provided a critical evidence base for reducing the burden of long-term renal toxicity without compromising curative outcomes.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Both cyclophosphamide and ifosfamide are nitrogen mustard alkylating agents used in Ewing sarcoma. What are their primary dose-limiting toxicities, and how does their metabolism explain the different toxicity profiles observed in this trial?

Key Response

Students must know that both agents require hepatic activation and produce acrolein (causing hemorrhagic cystitis, which is mitigated by mesna). However, ifosfamide uniquely produces chloroacetaldehyde, which causes neurotoxicity and significant renal tubular damage (Fanconi syndrome). This basic pharmacology directly explains the trial's rationale for seeking to replace ifosfamide with cyclophosphamide to spare renal function.

Resident

When evaluating a pediatric or young adult patient with standard-risk localized Ewing sarcoma for consolidation therapy, how do the results of the Euro-EWING99-R1 trial influence your choice between cyclophosphamide and ifosfamide, particularly regarding long-term survivorship?

Key Response

Residents need to apply this to practice. The trial proved non-inferiority of cyclophosphamide for event-free and overall survival while significantly reducing severe renal toxicity. In young patients with high cure rates, minimizing long-term morbidity like chronic kidney disease is paramount, making cyclophosphamide the preferred consolidation agent.

Fellow

The Euro-EWING99-R1 trial focused on standard-risk localized Ewing sarcoma. How should we approach consolidation therapy for high-risk or metastatic patients, and does the non-inferiority of cyclophosphamide observed here confidently extrapolate to those aggressive phenotypes?

Key Response

Fellows must recognize the boundaries of clinical trials. The trial specifically included standard-risk patients with good histologic response to induction or small tumor volume. Extrapolating non-inferiority to high-risk or metastatic disease is premature, as ifosfamide might have a dose-response or efficacy edge in harder-to-treat diseases that was not captured in this specific standard-risk cohort.

Attending

Transitioning from ifosfamide to cyclophosphamide represents a major de-escalation of toxicity. As an attending, how do you balance the statistical margin of a non-inferiority design with the clinical benefit of reduced late effects when counseling anxious parents who might equate 'less toxic' with 'less effective'?

Key Response

Attendings deal with complex communication. Non-inferiority trials define a margin where a small, clinically acceptable drop in efficacy is tolerated. Explaining that the survival outcomes are practically identical while the reduction in life-altering kidney damage is massive requires nuanced communication to reassure families that the cure is not being compromised.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In the Euro-EWING99-R1 trial, what are the methodological challenges in defining the non-inferiority margin for event-free survival in a rare pediatric tumor, and how do competing risks like treatment-related mortality impact the interpretation of this margin?

Key Response

PhDs focus on statistics and design. In rare diseases, sample sizes are limited, often forcing wider non-inferiority margins or relaxed alpha/beta errors. Furthermore, competing risks, such as lower treatment-related mortality in the cyclophosphamide arm, could artificially inflate its efficacy appearance compared to ifosfamide, making the choice of EFS versus OS critical.

Journal Editor

As a reviewer assessing this non-inferiority trial, how would you evaluate the impact of missing data, crossover, or dose-modifications on the per-protocol versus intention-to-treat analyses, given that per-protocol is often considered more conservative for non-inferiority designs?

Key Response

Editors know that in superiority trials, ITT is conservative. In non-inferiority trials, ITT can bias toward the null (non-inferiority) due to non-adherence or dose reductions, making the Per-Protocol (PP) analysis crucial. A strict reviewer would demand a robust comparison of both cohorts and flag high dropout rates in the toxic ifosfamide arm as potential confounders.

Guideline Committee

Based on the Euro-EWING99-R1 trial, should current NCCN and SIOP guidelines firmly recommend cyclophosphamide over ifosfamide as the category 1 preferred consolidation therapy for standard-risk localized Ewing sarcoma, and what level of evidence does this open-label RCT provide for such a shift?

Key Response

Committee members weigh practice-changing data. This trial provides Level 1 evidence (large, randomized, multicenter) for non-inferiority. Current guidelines have updated to reflect this, prioritizing cyclophosphamide-based consolidation (like VDC/IE alternating, or VAC) specifically to mitigate cumulative ifosfamide toxicity while maintaining equivalent survival outcomes in standard-risk cohorts.

Clinical Landscape

Noteworthy Related Trials

2003

INT-0091 Trial

n = 398 · NEJM

Tested

VDC (vincristine, doxorubicin, cyclophosphamide) alternating with IE (ifosfamide, etoposide)

Population

Patients with localized nonmetastatic Ewing sarcoma

Comparator

VDC alone

Endpoint

Event-free survival

Key result: The addition of ifosfamide and etoposide to VDC significantly improved 5-year event-free survival (69% vs 54%) and overall survival.

2012

Euro-Ewing Trial

n = 1154 · Lancet

Tested

VDC/IE chemotherapy

Population

Patients of all ages with newly diagnosed Ewing sarcoma

Comparator

VIDE (vincristine, ifosfamide, doxorubicin, etoposide) chemotherapy

Endpoint

Event-free survival

Key result: The VDC/IE regimen demonstrated superior event-free and overall survival, along with less severe toxicity, compared to the VIDE regimen.

2012

AEWS0031 Trial

n = 568 · JCO

Tested

Interval-compressed VDC/IE (every 14 days)

Population

Patients with localized Ewing sarcoma

Comparator

Standard-timing VDC/IE (every 21 days)

Endpoint

Event-free survival

Key result: Interval compression of the chemotherapy cycles improved 5-year event-free survival from 65% to 73% without increasing overall toxicity.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis